In a study on the effectiveness of galiellalactone in prostate cancer cells, Don-Doncow et al. showed that it acts as a cysteine reactive inhibitor and binds to one or more cysteines in STAT3 (Cys-367, Cys-468, Cys-542). Here, STAT3 is linked to prostate carcinoma.